Apellis Pharmaceuticals Appoints Mikael Dolsten to Board of Directors

Details

announced the election of Mikael Dolsten, M.D., Ph.D., to its Board of Directors, effective March 1, 2026. Dr. Dolsten, who is deemed 'independent' under Nasdaq rules, will receive compensation in the form of stock options and restricted stock units valued at $300,000 each, subject to vesting conditions. Additionally, he has entered into an indemnification agreement with the company, which may require the company to cover certain expenses he incurs in his role as a director.

Items reported

About Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.